-
ALSO READ
All claims against Dr Reddys dismissed in llitigation related to Revlimid
Auro Pharma's subsidiary get US FDA nod for MDS treatment drug
US Market gains ahead of inflation data
Natco Pharma named a defendant in an antitrust lawsuit in US
Dr Reddys Lab climbs after US court dismisses claims against generic Revlimid
-
FDA) for Saxagliptin Tablets, 2.5 mg and 5 mg, the generic version of Onglyza1 Tablets, 2.5 mg and 5 mg, of AstraZeneca AB. Glenmark's first tentative approval letter for Saxagliptin Tablets, 2.5 mg and 5 mg was received on 12 June 2017.
According to IQVIATM sales data for the 12-month period ending December 2022, the Onglyza Tablets, 2.5 mg and 5 mg market2 achieved annual sales of approximately $122.3 million.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Subscribe to Business Standard Premium
Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!
Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.
Download the Business Standard App for latest Business News and Market News .
RECOMMENDED FOR YOU